scholarly journals Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: Report of a case and literature review of kinase inhibitors and blocking antibodies

2014 ◽  
Vol 59 (6) ◽  
pp. 588 ◽  
Author(s):  
Shuchi Bansal ◽  
Kabir Sardana ◽  
Kishore Singh ◽  
VijayK Garg
2021 ◽  
Vol Volume 13 ◽  
pp. 45-53
Author(s):  
Liumei Shou ◽  
Tianyu Shao ◽  
Fangmin Zhao ◽  
Shuyi Chen ◽  
Qunwei Chen ◽  
...  

2008 ◽  
Vol 13 (9) ◽  
pp. 1001-1011 ◽  
Author(s):  
Mario E. Lacouture ◽  
Shenhong Wu ◽  
Caroline Robert ◽  
Michael B. Atkins ◽  
Heidi H. Kong ◽  
...  

2016 ◽  
Vol 175 (1) ◽  
pp. 216-217 ◽  
Author(s):  
M. Llamas‐Velasco ◽  
I. Hegyi ◽  
U. Hesterberg ◽  
E. Daudén ◽  
L. Requena ◽  
...  

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.


2017 ◽  
Vol 92 (4) ◽  
pp. 590-591 ◽  
Author(s):  
Anca Chiriac ◽  
Marius Florin Coros ◽  
Cristian Podoleanu ◽  
Simona Stolnicu

2021 ◽  
Vol 15 (2) ◽  
Author(s):  
Muhammad Darwin Prenggono ◽  
Alfi Yasmina ◽  
Misna Ariyah ◽  
Tenri Ashari Wanahari ◽  
Nuvita Hasrianti

Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using "chronic myeloid leukemia”, “tyrosine kinase inhibitors”, “imatinib”, “nilotinib”, “potassium”, “calcium”, “electrolytes” as keywords. This review used Pubmed-MEDLINE, Cochrane Library, and Google Scholar as electronic databases. Related 16 articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels tend to below the normal value. Tyrosine Kinase Inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely platelet-derived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of signs and symptoms.


Sign in / Sign up

Export Citation Format

Share Document